

Janssen LatAm

ASH 2022 Congress Guidebook



Disclaimers

© McNeil Panama LLC (hereinafter Janssen LatAm)

All rights reserved. The transmission of this e-mail is confidential and may contain privileged information directed only to the individual indicated in that e-mail address. If you are not the recipient of the email and you believe you received this email by mistake, please forward it to the sender so that we can deliver it to the appropriate recipient and delete this message from your inbox. You are receiving this email because you previously gave us your consent. We process your personal data in accordance with our Privacy Policy. For this end, please access the website www.janssen.com choose your country and consult the Privacy Policy or click on the link Contact us.

For any adverse events related report, please access the website www.janssen.com choose your country and click on Contact us.

*Argentina, Bolivia, Paraguay, Uruguay - infojanssen@janar.jnj.com;
Brazil - sac@janbr.jnj.com; Chile - infojanssen@jancl.jnj.com;
Colombia - infojanssen@janco.jnj.com;
Peru - infojanssen@janpe.jnj.com; Ecuador - infojanssen@janec.jnj.com;
Mexico - atencionaclientes@janmx.jnj.com;
Venezuela - infojanssen@janve.jnj.com;
Central America and Caribbean - infojanssen@janpa.jnj.com*


EM-116771. December, 2022.

Produced Exclusively for Healthcare Professionals







**Multiple
myeloma**



**Chronic
lymphocytic
leukemia**



**Mantle cell
lymphoma**





Oral Presentations



Posters



Educational Programs



Symposia





Oral Presentations



Posters



Educational Programs



Symposia





Oral Presentations



Posters





Saturday 10th December

09:30–11:00, R06–R09 (Ernest N. Morial Convention Center)

Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias: Basic and Translational

97

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Cortes-Selva et al.

[Abstract](#)

RRMM

100

Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens

Boyle et al.

[Abstract](#)

NDMM

09:30–11:00, 278–282 (Ernest N. Morial Convention Center)

Oral Session: 731. Autologous Transplantation: Clinical and Epidemiological: Multiple Myeloma and CHIP

116

Long-Term Outcome of a Prospective Randomized Trial Comparing Continuous Lenalidomide/Dexamethasone with Lenalidomide/Dexamethasone Induction, MEL140 with Autologous Blood Stem Cell Transplantation and Single Agent Lenalidomide Maintenance in Patients of Age 60-75 Years with Newly Diagnosed Multiple Myeloma

Straka et al.

[Abstract](#)

NDMM





Saturday 10th December

12:00–13:30, R02–R05 (Ernest N. Morial Convention Center)

Oral Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma

157

Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Phase 1/2 Results from MonumenTAL-1

Chari et al.

[Abstract](#)

RRMM

158

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Raje et al.

[Abstract](#)

RRMM

159

Efficacy and Safety of Elranatamab in Patients with Relapsed/Refractory Multiple Myeloma Naïve to B-Cell Maturation Antigen (BCMA)-Directed Therapies: Results from Cohort A of the MagnetisMM-3 Study

Bahlis et al.

[Abstract](#)

RRMM

160

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from one Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Searle et al.

[Abstract](#)

RRMM





Saturday 10th December

12:00–13:30, R02–R05 (Ernest N. Morial Convention Center)

Oral Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Bispecific Monoclonal Antibodies in Myeloma

161

RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
Carlo-Stella et al.

[Abstract](#)

RRMM

162

Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study

Wong et al.

[Abstract](#)

RRMM

12:30–13:30, 243–245 (Ernest N. Morial Convention Center)

Oral Session: 905. Outcomes Research—Lymphoid Malignancies: Health Outcomes in Plasma Cell Disorders and Transplant

171

Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study

Mian et al.

[Abstract](#)

NDMM/RRMM





Saturday 10th December

14:00–15:30, R02–R05 (Ernest N. Morial Convention Center)

Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM)

247

Isatuximab Plus Pomalidomide/Low-Dose Dexamethasone Versus Pomalidomide/Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma (ICARIA-MM): Characterization of Subsequent Antimyeloma Therapies
Richardson et al.

[Abstract](#)

RRMM

248

No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)
Lowther et al.

[Abstract](#)

RRMM

249

Comprehensive Characterization of Prolonged Unexplained Cytopenias in Relapsed/Refractory Multiple Myeloma Patients Following BCMA-Directed CAR-T Cell Therapy
Thibaud et al.

[Abstract](#)

RRMM





Saturday 10th December

14:00–15:30, R02–R05 (Ernest N. Morial Convention Center)

Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Relapsed and/or Refractory Myeloma (RRMM)

250

Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy

Reyes et al.

[Abstract](#)

RRMM

252

Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR-T Therapy

Peres et al.

[Abstract](#)

RRMM

16:00–17:30 **Great Hall AD**

(Ernest N. Morial Convention Center)

Oral Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT

361

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Usmani et al.

[Abstract](#)

RRMM





Saturday 10th December

16:00–17:30 Great Hall AD

(Ernest N. Morial Convention Center)

Oral Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT

364

Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPCR5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Bal et al.

[Abstract](#)

RRMM

366

FC-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens

Du et al.

[Abstract](#)

NDMM

16:00–17:30 208–210 (Ernest N. Morial Convention Center)

Oral Session: 905. Outcomes Research—Lymphoid Malignancies: Patient Representation and Equity in Hematologic Malignancies

384

A US National View of Prevalent and Newly Diagnosed Multiple Myeloma in 2021: A Retrospective Analysis of National All-Payer Claims Database

Lin et al.

[Abstract](#)

NDMM/RRMM





Sunday 11th December

09:30–11:00, New Orleans Theater C

(Ernest N. Morial Convention Center)

Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Prognostic Factors in Newly Diagnosed Multiple Myeloma (NDMM)

470

Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy

Maura et al.

[Abstract](#)

NDMM

472

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Perrot et al.

[Abstract](#)

NDMM

473

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone: Patient Reported Outcomes from GRIFFIN

Silbermann et al.

[Abstract](#)

NDMM





Sunday 11th December

12:00–13:30, *New Orleans Theater C*

(*Ernest N. Morial Convention Center*)

**Oral Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Novel Drugs and Optimized
Approaches in Myeloma**

566

Results from the First Phase 1 Clinical Study of the B-Cell Maturation Antigen (BCMA) Nex T Chimeric Antigen Receptor (CAR) T Cell Therapy CC-98633/BMS-986354 in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Costa et al.

[Abstract](#)

RRMM

567

Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity

Trudel et al.

[Abstract](#)

RRMM

568

Mezigdomide (CC-92480), a Potent, Novel Cereblon E3 Ligase Modulator (CELMoD), Combined with Dexamethasone (DEX) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Preliminary Results from the Dose-Expansion Phase of the CC-92480-MM-001 Trial

Richardson et al.

[Abstract](#)

RRMM





Sunday 11th December

12:00–13:30, New Orleans Theater C

(Ernest N. Morial Convention Center)

**Oral Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Novel Drugs and Optimized
Approaches in Myeloma**

569

A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial

Manier et al.

[Abstract](#)

NDMM

570

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant – Data from the Myeloma XI Trial

Pawlyn et al.

[Abstract](#)

NDMM





Monday 12th December

10:30–12:00, New Orleans Theater C

(Ernest N. Morial Convention Center)

Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Therapeutic Impact in Multiple Myeloma

751

Bortezomib-Melphalan-Prednisone (VMP) vs. Lenalidomide-Dexamethasone (Rd) in Transplant-Ineligible Real-Life Multiple Myeloma Patients: Updated Results of the Randomized Phase IV Real MM Trial

Bringhen et al.

[Abstract](#)

NDMM

752

Carfilzomib, Lenalidomide and Dexamethasone (KRd) vs Bortezomib, Lenalidomide, and Dexamethasone (VRd) as Induction Therapy in Newly Diagnosed High-Risk Multiple Myeloma

Tan et al.

[Abstract](#)

NDMM

753

Isatuximab Plus Carfilzomib and Dexamethasone in Patients with Early Versus Late Relapsed Multiple Myeloma: IKEMA Subgroup Analysis

Martin et al.

[Abstract](#)

RRMM





Monday 12th December

10:30–12:00, 288–290 (Ernest N. Morial Convention Center)

Oral Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Risk-adapted Treatment Strategies in Myeloma and Related Conditions

757

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the ASCENT Trial

Kumar et al.

[Abstract](#)

SMM

759

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone (Isa-KRd) in Patients with High-Risk Newly Diagnosed Multiple Myeloma: Planned Interim Analysis of the GMMG-Concept Trial

Weisel et al.

[Abstract](#)

NDMM

10:30–12:00, 393–396 (Ernest N. Morial Convention Center)

Oral Session: 705. Cellular Immunotherapies: Real World Outcomes and Special Populations Treated with Cellular Therapy

766

Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) who have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience

Ferreri et al.

[Abstract](#)

RRMM





Monday 12th December

14:45–16:15, Hall E (Ernest N. Morial Convention Center)

Oral Session: 651. Multiple Myeloma and Plasma Cell Dyscrasias Basic and Translational: Novel Therapeutic Strategies, Characterization of Response Biology, and Consequences

863

RG6234: A Novel 2:1 GPRC5D T Cell Bispecific Antibody Exhibits Best in Class Potential for the Treatment of Multiple Myeloma as a Monotherapy and in Combination

Eckmann et al.

[Abstract](#)

NDMM/RRMM

14:45–16:15, Great Hall BC

(Ernest N. Morial Convention Center)

Oral Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: New Approaches to MRD Assessment

868

Early and Sustained Undetectable Measurable Residual Disease (MRD) after Idecabtagene Vicleucel (Ide-cel) Defines a Subset of Multiple Myeloma (MM) Patients in KarMMa Achieving Prolonged Survival

Paiva et al.

[Abstract](#)

RRMM

869

Differences in Single Cells Between BCMA-Targeting CAR T-Cell Therapy Responders and Non-Responders Reveals Initial Resistance and Acquired Resistance are Driven by Different Factors

Samur et al.

[Abstract](#)

RRMM





Monday 12th December

16:30–18:00, La Nouvelle Orleans Ballroom AB

(Ernest N. Morial Convention Center)

Oral Session: 902. Health Services and Quality—Lymphoid Malignancies: Time for Change: Health Care Delivery and Disparities

993

Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

Bansal et al.

[Abstract](#)

RRMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 652. Multiple Myeloma and Plasma Cell

Dyscrasias: Clinical and Epidemiological: Poster I

1856

Effectiveness and Safety of Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma in Real-Life Setting: The ALFA Study

Leleu et al.

[Abstract](#)

RRMM

1859

Global Treatment Standard in Multiple Myeloma Remains Elusive: Updated Results from the INSIGHT MM Global, Prospective, Observational Study

Puig et al.

[Abstract](#)

NDMM/RRMM

1867

Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Visram et al.

[Abstract](#)

RRMM

1878

Comparative Effectiveness of Lenalidomide/Dexamethasone-Based Triplet Regimens for Treatment of Relapsed and/or Refractory Multiple Myeloma in Subgroups Defined By Cytogenetic Risk

Sanchez et al.

[Abstract](#)

RRMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I

1880

Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma in a Real-Life Population in France:

The REMIX Study

Leleu et al.

[Abstract](#)

RRMM

1883

Characteristics and Outcomes in Patients with Lenalidomide-Refractory Relapsed/Refractory Multiple Myeloma Treated with 1-3 Prior Lines of Therapy: Analysis of the Individual Patient-Level Data from Daratumumab Clinical Trials

Dhakal et al.

[Abstract](#)

RRMM

1884

Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Sweiss et al.

[Abstract](#)

RRMM

1891

Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Richter et al.

[Abstract](#)

RRMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 652. Multiple Myeloma and Plasma Cell Dyscrasias: Clinical and Epidemiological: Poster I

1894

Efficacy of Frontline Treatments for Newly Diagnosed Transplant-Ineligible Multiple Myeloma, a Network Meta-Analysis

Wong et al.

[Abstract](#)

NDMM

1897

A Brazilian Real-Life Experience of Multiple Myeloma Patients: Final Results from the MMyBRave Multi-Center Study

Hungria et al.

[Abstract](#)

NDMM/RRMM

1911

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 mg/kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Miao et al.

[Abstract](#)

RRMM

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: Session: 653. Myeloma and Plasma Cell Dyscrasias: Prospective Therapeutic Trials: Poster I

1916

Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)

Bhutani et al.

[Abstract](#)

NDMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

**Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Poster I**

1918

Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

Lonial et al.

[Abstract](#)

RRMM

1919

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell–Redirecting Antibody, as Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Voorhees et al.

[Abstract](#)

RRMM

1920

A Phase 1/2, Dose and Schedule Evaluation Study to Investigate the Safety and Clinical Activity of Belantamab Mafodotin Administered in Combination with Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma

Terpos et al.

[Abstract](#)

NDMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Poster I

1921

Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 MagnetisMM-5 Study Safety Lead-in Cohort

Grosicki et al.

[Abstract](#)

RRMM

1923

Subcutaneous Isatuximab Administration by an On-Body Delivery System (OBDS) in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: Phase 1b Expansion Study Results

Quach et al.

[Abstract](#)

RRMM

1924

Enduring Responses After 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Lesokhin et al.

[Abstract](#)

RRMM

1925

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Cohen et al.

[Abstract](#)

RRMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Poster I

1927

Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65 ; < 80 Years).

IFM2020-05/Benefit

Bobin et al.

[Abstract](#)

NDMM

1929

Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis

Lee et al.

[Abstract](#)

AL

1930

Quadruplet Induction, Autologous Transplantation and Minimal Residual Disease Adapted Consolidation and Treatment Cessation in Older Adults ≥ 70 y with Newly Diagnosed Multiple Myeloma: A Subgroup Analysis of the MASTER Trial

Giri et al.

[Abstract](#)

NDMM

1932

Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/Refractory Multiple Myeloma

Kumar et al.

[Abstract](#)

RRMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

**Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Poster I**

1934

Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Bhutani et al.

[Abstract](#)

NDMM

1936

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Otero et al.

[Abstract](#)

RRMM

1937

Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma Treated with Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody: Patient-Reported Outcomes from MonumenTAL-1

Touzeau et al.

[Abstract](#)

RRMM

1938

Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting

Parrondo et al.

[Abstract](#)

RRMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:

Prospective Therapeutic Trials: Poster I

1939

Multicenter Open Label Phase 2 Study of Isatuximab Plus Pomalidomide and Dexamethasone with Carfilzomib in Relapsed or Refractory Multiple Myeloma. IsKPD - IFM2018-03

Bobin et al.

[Abstract](#)

RRMM

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 704. Cellular Immunotherapies: Early Phase and

Investigational Therapies: Poster I

1994

Phase II Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Chen et al.

[Abstract](#)

RRMM

1998

Bispecific CS1-BCMA CAR-T Cells are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study

Mei et al.

[Abstract](#)

RRMM

2004

Interim Phase I Clinical Data of FT576 as Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma

Dhakal et al.

[Abstract](#)

RRMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster I

2019

Universal Updated Phase 1 Data Highlights Role of Allogeneic Anti-BCMA ALLO-715 Therapy for Relapsed/Refractory Multiple Myeloma

Mailankody et al.

[Abstract](#)

RRMM

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I

2023

DVRd Followed by Ciltacabtagene Autoleucel Versus DVRd Followed by ASCT in Patients with Newly Diagnosed Multiple Myeloma who are Transplant Eligible: A Randomized Phase 3 Study (EMagine/CARTITUDE-6)

Boccardo et al.

[Abstract](#)

NDMM

2027

Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience

Hashmi et al.

[Abstract](#)

RRMM

2028

Efficacy and Safety of Cilta-Cel in Patients with Progressive Multiple Myeloma after Exposure to Non-Cellular Anti-BCMA Immunotherapy

Cohen et al.

[Abstract](#)

RRMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster I

2030

Efficacy Outcomes and Characteristics of Patients with Multiple Myeloma (MM) who Achieved Sustained Minimal Residual Disease Negativity after Treatment with Ciltacabtagene Autoleucel (cilta-cel) in CARTITUDE-1

Munshi et al.

[Abstract](#)

RRMM

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster I

2110

Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus RVd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the DETERMINATION Phase 3 Trial

Hassoun et al.

[Abstract](#)

NDMM





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 903. Health Services and Quality–Myeloid

Malignancies: Poster I

2236

Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma

Reyes et al.

[Abstract](#)

RRMM

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 905. Outcomes Research—Lymphoid

Malignancies: Poster I

2283

Impact of Disease Progression, Line of Therapy, and Response on Health-Related Quality of Life in Multiple Myeloma: A Systematic Literature Review

Fonseca et al.

[Abstract](#)

NDMM/RRMM

2284

Burden of Hospitalization Before and After a Disease Progression Following Triple-Class Exposure in Patients with Relapsed and Refractory Multiple Myeloma

Harper et al.

[Abstract](#)

RRMM

2291

Light-Chain Amyloidosis in Sweden (2011–2019): Incidence, Disease Burden, and Clinical Outcomes in Real-World Patients

Mellqvist et al.

[Abstract](#)

AL





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 905. Outcomes Research—Lymphoid

Malignancies: Poster I

2297

Patients' and Caregivers' Perspectives from Social Media Towards Disease Burden and Innovative Treatment Options in Multiple Myeloma

Lin et al.

[Abstract](#)

NDMM/RRMM

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 906. Outcomes Research—Myeloid Malignancies: Poster I

2317

Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Receiving ≥ 3 Lines of Therapy: A Real-World Evaluation in the United States

Girvan et al.

[Abstract](#)

RRMM

2321

Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States

Ma et al.

[Abstract](#)

RRMM





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 651. Multiple Myeloma and Plasma Cell

Dyscrasias: Basic and Translational: Poster II

3166

Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)

Boss et al.

[Abstract](#)

RRMM

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 652. Multiple Myeloma and Plasma Cell

Dyscrasias: Clinical and Epidemiological: Poster II

3176

Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed Multiple Myeloma: IKEMA Subgroup Analysis By Number of Prior Lines of Treatment

Capra et al.

[Abstract](#)

RRMM

3187

Daratumumab, Pomalidomide and Dexamethasone (DPd) Versus Daratumumab, Velcade and Dexamethasone (DVd) in Previously Treated Daratumumab Naïve Relapsed Refractory Multiple Myeloma Patients

Ouchveridze et al.

[Abstract](#)

RRMM





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 652. Multiple Myeloma and Plasma Cell

Dyscrasias: Clinical and Epidemiological: Poster II

3192

Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma

Elmeliegy et al.

[Abstract](#)

RRMM

3200

Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database

Leblanc et al.

[Abstract](#)

RRMM

3201

Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study

Cavo et al.

[Abstract](#)

NDMM

3213

Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Pro prospective Italian Observational Study

Offidani et al.

[Abstract](#)

RRMM





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 652. Multiple Myeloma and Plasma Cell

Dyscrasias: Clinical and Epidemiological: Poster II

3225

Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience

Hultcrantz et al.

[Abstract](#)

RRMM

3228

Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Willemin et al.

[Abstract](#)

RRMM

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:

Prospective Therapeutic Trials: Poster II

3234

Ocular Adverse Events in Transplant Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Belantamab Mafodotin, Lenalidomide, and Dexamethasone in a Phase 1/2 Trial

Terpos et al.

[Abstract](#)

NDMM

3236

Subcutaneous Daratumumab Plus Pomalidomide and Dexamethasone (D-Pd) Versus Pomalidomide and Dexamethasone (Pd) Alone in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): Overall Survival Results from the Phase 3 APOLLO Study

Dimopoulos et al.

[Abstract](#)

RRMM





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Poster II

3237

Outcomes of MRD-Adapted Treatment Modulation in Patients with Newly Diagnosed Multiple Myeloma Receiving Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) and Autologous Transplantation: Extended Follow up of the MASTER Trial

Costa et al.

[Abstract](#)

NDMM

3238

Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of GRIFFIN Among Clinically Relevant Subgroups

Chari et al.

[Abstract](#)

NDMM

3239

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)

O'Donnell et al.

[Abstract](#)

NDMM

3240

Updated Interim Results from a Phase 1 Study of HPN217, a Half-Life Extended Tri-Specific T Cell Activating Construct (TriTAC®) Targeting B Cell Maturation Antigen (BCMA) for Relapsed/Refractory Multiple Myeloma (RRMM)

Abdallah et al.

[Abstract](#)

RRMM





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:

Prospective Therapeutic Trials: Poster II

3241

Belantamab Mafodotin in Combination with VRd for the Treatment of Newly Diagnosed Transplant Eligible Multiple Myeloma Patients: Results from the Phase II, Open Label, Multicenter, GEM-BELA-VRd Trial

Gonzalez-Calle et al.

[Abstract](#)

NDMM

3242

MajesTEC-4 (EMN30): A Phase 3 Trial of Teclistamab + Lenalidomide Versus Lenalidomide Alone As Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma

Zamagni et al.

[Abstract](#)

NDMM

3243

MonumentAL-5: A Phase 3 Study of Talquetamab Versus Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma Who Received ≥ 4 Prior Lines of Therapy, Including a Proteasome Inhibitor, an Immunomodulatory Drug, and an Anti-CD38 Monoclonal Antibody

Kumar et al.

[Abstract](#)

RRMM

3244

Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Kastritis et al.

[Abstract](#)

AL Amyloidosis





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Poster II

3245

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 MAIA Study

Moreau et al.

[Abstract](#)

NDMM

3246

Single-Agent Belantamab Mafodotin in Patients with Relapsed or Refractory Multiple Myeloma: Final Analysis of the DREAMM-2 Trial

Nooka et al.

[Abstract](#)

RRMM

3248

Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma

Trudel et al.

[Abstract](#)

RRMM

3251

Daratumumab Based Response Adapted Therapy for Older Adults with Newly Diagnosed Multiple Myeloma: Interim Analysis of Phase II Study

Baz et al.

[Abstract](#)

NDMM





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:

Prospective Therapeutic Trials: Poster II

3253

Isatuximab in Combination with Lenalidomide and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma: Updated Safety Run-in Results from the Randomized Phase 3 ITHACA Study

Mateos et al.

[Abstract](#)

SMM

3257

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma

Rodriguez et al.

[Abstract](#)

RRMM

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II

3311

Updated Results of FUMANBA-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Li et al.

Li et al.

[Abstract](#)

RRMM

3313

Phase 1 Study of CART-ddBCMA for the Treatment of Subjects with Relapsed and / or Refractory Multiple Myeloma

Frigault et al.

[Abstract](#)

RRMM





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)
Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II

3314

KarMMA-2 Cohort 2c: Efficacy and Safety of Idecabtagene Vicleucel in Patients with Clinical High-Risk Multiple Myeloma Due to Inadequate Response to Frontline Autologous Stem Cell Transplantation

Dhodapkar et al.

[Abstract](#)

NDMM

18:00–20:00, Hall D (Ernest N. Morial Convention Center)
Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II

3354

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

Van De Donk et al.

[Abstract](#)

RRMM

3357

Phase 2, Open-Label Study of Ciltacabtagene Autoleucel, an Anti-BCMA CAR-T Cell Therapy, in Chinese Patients with Relapsed/Refractory Multiple Myeloma (CARTIFAN-1): 26-Month Median Follow-up

Mi et al.

[Abstract](#)

RRMM





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

731. Autologous Transplantation: Clinical and Epidemiological: Poster II

3428

Daratumumab (Dara), Cyclophosphamide, Thalidomide and Dexamethasone for Transplant Eligible Newly Diagnosed Multiple Myeloma (TE NDMM) Patients: Response Rate Impacts on PFS
De Queiroz Crusoe et al.

[Abstract](#)

NDMM





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 652. Multiple Myeloma and Plasma Cell

Dyscrasias: Clinical and Epidemiological: Poster III

4491

Efficacy and Safety of Oral Ixazomib (Ixa), Intravenous (IV) Daratumumab (Dara), and IV/Oral Dexamethasone (Dex; IDd) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM) and 1–3 Prior Therapies: Results of the Final Analysis of a Phase 2 Study

Delimpasi et al.

[Abstract](#)

RRMM

4497

Post-Hoc Analysis of Efficacy and Safety in the SWOG S0777 Trial Stratified By Age

Durie et al.

[Abstract](#)

NDMM

4509

A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Elmeliegy et al.

[Abstract](#)

RRMM

4516

Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

Schiller et al.

[Abstract](#)

RRMM





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 652. Multiple Myeloma and Plasma Cell

Dyscrasias: Clinical and Epidemiological: Poster III

4527

Humoral Immune Reconstitution Following Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Hematopoietic Cell Transplantation (AHCT) and MRD-Response-Adapted Treatment Cessation

Schmidt et al.

[Abstract](#)

NDMM

4549

Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study

Hultcrantz et al.

[Abstract](#)

RRMM

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:

Prospective Therapeutic Trials: Poster III

4551

Trial in Progress: A Phase II Window of Opportunity Study of the BCMAxCD3 Bispecific Antibody REGN5458 in Previously Untreated Patients with Symptomatic Multiple Myeloma

Ferreri et al.

[Abstract](#)

NDMM





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

**Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Poster III**

4552

A Phase II Multicenter Clinical Trial Assessing the Safety and Efficacy of Ixazomib Pomalidomide Dexamethasone Combination As Second or Third-Line Treatment for Patients with Triple Exposed Relapsed and Refractory Multiple Myeloma: Prespecified Interim Analysis (IPoD-790 trial)

Cohen et al.

[Abstract](#)

RRMM

4553

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: MAIA Age Subgroup Analysis

Facon et al.

[Abstract](#)

NDMM

4554

Intravenous and Subcutaneous Administration of RG6234, a Novel GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Biomarker Results from a Phase I Study

Bröske et al.

[Abstract](#)

RRMM

4555

Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study

Bumma et al.

[Abstract](#)

RRMM





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Poster III

4556

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes

Kumar et al.

[Abstract](#)

NDMM

4557

Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the GRIFFIN and MASTER Studies

Callander et al.

[Abstract](#)

NDMM

4558

MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

Krishnan et al.

[Abstract](#)

NDMM





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:
Prospective Therapeutic Trials: Poster III

4559

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 MAIA Study
Kumar et al.

[Abstract](#)

NDMM

4560

An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 GRIFFIN Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)
Nooka et al.

[Abstract](#)

NDMM

4561

Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Versus Bortezomib, Melphalan, and Prednisone (VMP) Alone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of the Phase 3 ALCYONE Study
Mateos et al.

[Abstract](#)

NDMM

4563

Phase 2 Study of Daratumumab (DARA) Plus Bortezomib, Cyclophosphamide, and Dexamethasone (D-VCd) in Patients with Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis: AQUARIUS
Santhorawala et al.

[Abstract](#)

AL Amyloidosis





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 653. Myeloma and Plasma Cell Dyscrasias:

Prospective Therapeutic Trials: Poster III

4567

MagnetisMM-4: An Open Label, Phase 1B/2 Umbrella Study of Elranatamab in Combination with Other Anti-Cancer Treatments for Patients with Multiple Myeloma

Landgren et al.

[Abstract](#)

RRMM

4572

Randomized Comparison between KRd and KTd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and QoL Data (AGMT-MM02 Trial)

Ludwig et al.

[Abstract](#)

NDMM

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 705. Cellular Immunotherapies: Late Phase and

Commercially Available Therapies: Poster III

4659

Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience

Sidana et al.

[Abstract](#)

RRMM

4677

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Khoury et al.

[Abstract](#)

RRMM





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 731. Autologous Transplantation: Clinical and Epidemiological: Poster III

4750

Outcomes of Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Responded to Daratumumab, Pomalidomide and Dexamethasone (DPd), Followed By High Dose Chemotherapy/Autologous Stem Cell Transplantation (HDCT/ASCT) Versus (DPd) Alone

Jain et al.

[Abstract](#)

RRMM

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 905. Outcomes Research—Lymphoid Malignancies: Poster III

4918

Estimation of Long-Term Post-Infusion Costs of Care for Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Following Administration of Idecabtagene Vicleucel (ide-cel, bb2121) in the KarMMa Clinical Trial

Patwardhan et al.

[Abstract](#)

RRMM





Saturday 10th December

09:30–10:45, *Great Hall AD*

(Ernest N. Morial Convention Center)

Multiple Myeloma: Assessing the Patient and the Disease

Chair: Natalie Callander

[Program information](#)

- Fitness and Frailty in Myeloma
 - Ciara L. Freeman
- High or Low? Assessing Disease Risk in Multiple Myeloma
 - Timothy Martin Schmidt
- The Burden of Myeloma: Novel Approaches to Disease Assessment
 - Taxiarchis Kourelis

16:00–17:15, *Hall E*

(Ernest N. Morial Convention Center)

Immunotherapy in Multiple Myeloma

Chair: Suzanne Trudel

[Program information](#)

- Cellular Therapy for Multiple Myeloma: What's Now and What's Next
 - Paula Rodriguez Otero
- Antibodies and Bispecifics for Multiple Myeloma: Effective Effector Therapy
 - Suzanne Trudel
- Beyond the Cell: Novel Non-Cellular Immunotherapy Approaches to Multiple Myeloma
 - Sarah A. Holstein





Monday 12th December

14:45–16:00, *Great Hall AD*

(Ernest N. Morial Convention Center)

Treatment Approaches for the Multiple Myeloma Patient in 2022

Chair: Yvonne A. Efebera

[Program information](#)

- The Consultant's Guide to Smoldering Multiple Myeloma
 - Sigrun Thorsteinsdottir
- Newly Diagnosed Multiple Myeloma: Making Sense of the Menu
 - Caitlin Costello
- The First Relapse in Multiple Myeloma – How to Pick the Next Best Thing
 - Yvonne A. Efebera





Friday 9th December

07:00–10:00, Grand Ballroom C (Sheraton New Orleans)

The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

Chair: Nikhil C. Munshi

[Program information](#)

Sponsored by AbbVie, Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Pfizer.

07:00–10:00, Virtual Program

Putting the CAR(T) Before the Horse: Practicalities of T Cell-Activating Therapies in Multiple Myeloma

Chairs: Hearn J. Cho, Paul G. Richardson, A. Keith Stewart

[Program information](#)

Sponsored by The Multiple Myeloma Research Foundation with funding provided by Bristol Myers Squibb, Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC., and Legend Biotech USA Inc.





Friday 9th December

11:00–14:00, Elite B (Hyatt Regency New Orleans)

A Conversation With the Myeloma Experts: Making Sense of the Evolving Treatment Landscape

Chair: Brian G.M. Durie

[Program information](#)

Sponsored by Amgen, Janssen Biotech, Inc., Karyopharm Therapeutics Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., and Takeda Pharmaceuticals U.S.A., Inc. Provided by CCO in partnership with IMF

**11:00–14:00, Great Hall BC
(Ernest N. Morial Convention Center)**

Exploiting BCMA in the Treatment of Multiple Myeloma: How Could Bispecific Antibodies and T-Cell Engagement Impact Relapsed/ Refractory Disease?

Chair: Sundar Jagannath

[Program information](#)

Sponsored by Regeneron Pharmaceuticals, Inc.

11:00–14:00, 343–345 (Ernest N. Morial Convention Center)

MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes

Speakers: Ola Landgren, Aaron C. Logan, Stephen P. Mulligan

[Program information](#)

Sponsored by AbbVie, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme

11:00–14:00, Empire CD (Hyatt Regency New Orleans)

Rapidly Evolving Paradigms in Multiple Myeloma: Applying Current Data in the Clinic

Chair: Ajai Chari

[Program information](#)

Sponsored by Bristol Myers Squibb, Janssen Biotech, Inc., GlaxoSmithKline, Karyopharm Therapeutics, and Sanofi.





Friday 9th December

15:00–18:00, Elite B (Hyatt Regency New Orleans)

AL Amyloidosis: Advances in Early Diagnosis, Treatment Options, and Individualized Care

Chair: Angela Dispenzieri

[Program information](#)

Sponsored by educational grants from Alexion Pharmaceuticals and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC. Provided by Clinical Care Options, LLC.

19:00–22:00, Celestin ABCD (Hyatt Regency New Orleans)

Addressing Current Questions and Controversies in the Management of Multiple Myeloma - What Clinicians Want to Know (Part 3 of a 3-part CME-accredited Symposia Series)

Chair: Neil Love

[Program information](#)

Sponsored by educational grants from Bristol Myers Squibb, GlaxoSmithKline, Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC, Karyopharm Therapeutics, and Sanofi Genzyme





Abbreviations

ADC, antibody-drug conjugate

AHCT, autologous hematopoietic cell transplantation

AL, amyloid light chain

ALNUC, alnuctamab

ASCT, autologous stem cell transplantation

BCMA, B-cell maturation antigen

Belmaf, belantamab mafodotin

CAR, chimeric antigen receptor

CD, cluster of differentiation

CELMoD, cereblon E3 ligase modulator

Cilta-cel, ciltacabtagene autoleucel

CMRG, Canadian Myeloma Research Group

CR, complete response

CRS, cytokine release syndrome

CS1, CD319, SLAMF7

Dara, daratumumab

Dara-KRd, daratumumab, carfilzomib, lenalidomide and dexamethasone

Dex, dexamethasone

DPd, daratumumab, pomalidomide and dexamethasone

D-Rd, daratumumab, lenalidomide and dexamethasone

D-RVd, daratumumab, lenalidomide, bortezomib and dexamethasone

D-VCd, daratumumab, bortezomib, cyclophosphamide and dexamethasone

DVd, daratumumab, velcade and dexamethasone

D-VMP, daratumumab, bortezomib, melphalan and prednisone





Abbreviations

FC, fragment crystallizable

GPRC5D, G-protein coupled receptor family C group 5 member D

HDCT, high dose chemotherapy

HRCA, high-risk cytogenetic abnormalities

IBER, iberdomide

IDd, ixazomib, daratumumab and dexamethasone

Ide-cel, idecabtagene vicleucel

IV, intravenous

Ixa, ixazomib

K, carfilzomib

KRd, carfilzomib, lenalidomide and dexamethasone

KTd, carfilzomib, lenalidomide and dexamethasone

LCI, Levine Cancer Institute

MEL140, melphalan 140

MM, multiple myeloma

MRD, minimal residual disease

NDMM, newly diagnosed multiple myeloma

OBDS, on-body delivery system

Pd, pomalidomide and dexamethasone

PFS, progression-free survival

Pts, patients

QoL, quality of life

Rd, lenalidomide and dexamethasone

R/R, relapsed/refractory

RRMM, relapsed/refractory multiple myeloma





Abbreviations

RVd, lenalidomide, bortezomib and dexamethasone

SC, subcutaneous

SMM, smoldering multiple myeloma

SWOG, Southwest Oncology Group

TCE, T-cell engager

TCR, T-cell receptor

Tec-DR, teclistamab, daratumumab and lenalidomide

TriTAC®, tri-specific T cell activating construct

U.S., United States

VMP, bortezomib, melphalan and prednisone

VRd, bortezomib, lenalidomide and dexamethasone

XKd, selinexor, carfilzomib and dexamethasone





Saturday 10th December

09:30–11:00, La Nouvelle Orleans Ballroom AB
(Ernest N. Morial Convention Center)

Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations

91

MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study

Munir et al.

[Abstract](#)

92

Treatment Outcomes after Undetectable MRD with First-Line Ibrutinib (Ibr) Plus Venetoclax (Ven): Fixed Duration Treatment (Placebo) Versus Continued Ibr with up to 5 Years Median Follow-up in the CAPTIVATE Study

Allan et al.

[Abstract](#)

93

Residual Disease Kinetics Among Patients with High-Risk Factors Treated with First-Line Fixed-Duration Ibrutinib Plus Venetoclax (Ibr+Ven) Versus Chlorambucil Plus Obinutuzumab (Clb+O): The GLOW Study

Niemann et al.

[Abstract](#)





Saturday 10th December

**09:30–11:00, La Nouvelle Orleans Ballroom AB
(Ernest N. Morial Convention Center)**

Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Doublet Combinations

94

Combination of Ibrutinib Plus Venetoclax with MRD-Driven Duration of Treatment Results in a Higher Rate of MRD Negativity in IGHV Unmutated Than Mutated CLL: Updated Interim Analysis of FLAIR Study

Munir et al.

[Abstract](#)

95

Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data

Jain et al.

[Abstract](#)

**14:00–15:30, New Orleans Theater C
(Ernest N. Morial Convention Center)**

Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III

232

Phase 1/2 Study of Zilovetamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Lee et al.

[Abstract](#)





Saturday 10th December

16:00–17:30, R06–R09 (Ernest N. Morial Convention Center)
Oral Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Targeted Triplet Combinations and Richter's Transformation

343

Final Analysis of the Prospective Multicenter CLL2-Give Trial of Obinutuzumab (GA101, G), Ibrutinib (I), and Venetoclax (Ve) in Untreated Patients with CLL with 17p Deletion/*TP53* Mutation

Huber et al.

[Abstract](#)

344

Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease

Ryan et al.

[Abstract](#)

345

Genetic Markers and Front Line FCR/BR Vs. RVe, GVe and GIVe Treatment – Outcome Results from the CLL13/GAIA Trial

Tausch et al.

[Abstract](#)

346

High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without *TP53* Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Furstenau et al.

[Abstract](#)





Monday 12th December

10:30–12:00, 388–390 (Ernest N. Morial Convention Center)

Oral Session: 905. Outcomes Research—Lymphoid

Malignancies: Outcomes in Lymphoma

797

Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib

Versus Acalabrutinib

Jacobs et al.

[Abstract](#)

16:30–18:00, 243–245 (Ernest N. Morial Convention Center)

Oral Session: 642. Chronic Lymphocytic Leukemia:

Clinical and Epidemiological: Drugs in Development and COVID-19

961

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Mato et al.

[Abstract](#)





Tuesday 13th December

09:00–10:30, Hall E (Ernest N. Morial Convention Center)
General Sessions: Late-Breaking Abstracts Session

LBA-6

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Brown et al.

[Abstract](#)





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I

1587

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Shadman et al.

[Abstract](#)

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

1797

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Shah et al.

[Abstract](#)

1800

Exploratory Results of PET-CT and Residual Lymph Node Fine Needle Aspiration of Patients Treated with First-Line Venetoclax and Ibrutinib for CLL/SLL; First Interim Analysis of the Phase 2 HOVON 158/Next STEP Trial

Levin et al.

[Abstract](#)





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

1801

High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

Kim et al.

[Abstract](#)

1802

Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy

Archibald et al.

[Abstract](#)

1808

Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Roeker et al.

[Abstract](#)

1809

Initiating First-Line (1L) Ibrutinib (Ibr) in Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Improves Overall Survival (OS) Outcomes to Rates Approximating an Age-Matched Population of ≥ 65 Years

Ghia et al.

[Abstract](#)





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

1813

Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib

Itsara et al.

[Abstract](#)

1817

Real-World Outcome of Treatment with Single-Agent Ibrutinib in Patients with Chronic Lymphocytic Leukemia: Results from the Italian Study EVIDENCE

Mauro et al.

[Abstract](#)





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II

3115

Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

Quinquenel et al.

[Abstract](#)

3117

A Fixed-Duration Immunochemotherapy Approach Combined with Ibrutinib in CLL Produces Deep and Sustained MRD Responses: 5.5-Year Results from the ICLL-07 Filo Trial

Michallet et al.

[Abstract](#)

3122

Real World Comparison of Bruton Tyrosine Kinase Inhibitors and Venetoclax in Patients Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Roeker et al.

[Abstract](#)





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II

3123

Real-World Treatment (Tx) Patterns and Clinical Outcomes Among Patients (Pts) with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Who Received at Least 2 Prior Lines of Therapy Including Bruton Tyrosine Kinase Inhibitor (BTKi) and/or B-Cell Lymphoma 2 Inhibitor (BCL2i)

Awan et al.

[Abstract](#)

3124

Combined Treatment with Ibrutinib and Anti-CD38 Monoclonal Antibody Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia with *TP53* Aberrations: Results of the Filo Phase II Study IDA53

Aurran-Schleinitz et al.

[Abstract](#)

3129

Real-World Outcomes of Second-Line Chronic Lymphocytic Leukemia Treatments: Retrospective Analysis of the Brazilian Registry of CLL

Pitombeira de Lacerda et al.

[Abstract](#)





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster II

3132

Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry

Ghosh et al.

[Abstract](#)

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: Poster II

3319

ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

Dauids et al.

[Abstract](#)

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 905. Outcomes Research—Lymphoid Malignancies: Poster II

3578

Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib

Jacobs et al.

[Abstract](#)





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III

4431

Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up

Byrd et al.

[Abstract](#)

4434

Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Furman et al.

[Abstract](#)

4437

Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Wang et al.

[Abstract](#)

4439

Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy

Wang et al.

[Abstract](#)





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III

4443

Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the SNDS Database (OSIRIS)

Choquet et al.

[Abstract](#)

[Abstract](#)

4446

Time-Limited Maintenance with Ibrutinib after First-Line Therapy and the Incremental Impact on Minimal Residual Disease (MRD) for Patients with Chronic Lymphocytic Leukemia (CLL)

Parrondo et al.

[Abstract](#)

4447

Overall and Subgroup Results from the Third Interim Analysis of FIRE, a Real-World Study of Ibrutinib Treatment for CLL/SLL in France

Dartigeas et al.

[Abstract](#)

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 905. Outcomes Research—Lymphoid Malignancies: Poster III

4934

Early Adherence and Persistence to First-Line Ibrutinib or Acalabrutinib Among Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Atrial Fibrillation

Srivastava et al.

[Abstract](#)





Sunday 11th December

09:30–10:45, 265–268

(Ernest N. Morial Convention Center)

Maximizing Outcomes in CLL

Chair: Jennifer R. Brown

[Program information](#)

- Selecting Initial Therapy in CLL
 - Jennifer R. Brown
- Novel Therapies and Combinations in CLL Refractory to BTK Inhibitors and Venetoclax
 - Lydia Scarfò
- Treatment of Richter's Syndrome
 - Tanya Siddiqi





Friday 9th December

11:00–14:00, 343–345 (Ernest N. Morial Convention Center)

MRD Assessment as a Cornerstone to Clinical Decision-Making in Hematologic Malignancies: Techniques, Utilization, and Best Practices to Optimize Patient Outcomes

Speakers: Ola Landgren, Aaron C. Logan, Stephen P. Mulligan

[Program information](#)

Sponsored by AbbVie, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, and Sanofi Genzyme

11:00–14:00, Empire A (Hyatt Regency New Orleans)

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care with Groundbreaking Treatment

Chair: John G. Gribben

[Program information](#)

Sponsored by AbbVie, AstraZeneca, BeiGene, Bristol Myers Squibb, Lilly, Merck & Co., Inc., and Pharmacyclics LLC, an AbbVie Company; and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.





Friday 9th December

11:00–14:00, *Celestin ABCD (Hyatt Regency New Orleans)*

Addressing Current Questions and Controversies in the Management of Chronic Lymphocytic Leukemia - What Clinicians Want to Know (Part 1 of a 3-part CME-accredited Symposia Series)

Chair: Neil Love

[Program information](#)

Sponsored by educational grants from AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Genentech, a member of the Roche Group, Lilly; Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech Inc., administered by Janssen Scientific Affairs LLC.





Abbreviations

1L, first-line

AVO, acalabrutinib, venetoclax and obinutuzumab

BCL2, B-cell lymphoma 2

BCL2i, B-cell lymphoma 2 inhibitor

BR, bendamustine and rituximab

BTK, Bruton tyrosine kinase

BTKi, Bruton tyrosine kinase inhibitor

CAR, chimeric antigen receptor

CIT, chemoimmunotherapy

Clb+O, chlorambucil and obinutuzumab

CLL, chronic lymphocytic leukemia

COVID-19, coronavirus disease 2019

FCR, fludarabine, cyclophosphamide and rituximab

G/GA101, obinutuzumab

GVe, obinutuzumab and venetoclax

GIVe, obinutuzumab, ibrutinib and venetoclax

I/Ibr, ibrutinib

IGHV, immunoglobulin heavy chain

IV/Ibr+Ven, ibrutinib and venetoclax

MCL, mantle cell lymphoma

MRD, minimal disease residue

MZL, marginal zone lymphoma

OS, overall survival

PET-CT, positron emission tomography-computed tomography

PFS, progression-free survival

Pts, patients





Abbreviations

R/R, relapsed/refractory

RVe, rituximab and venetoclax

SLL, small lymphocytic lymphoma

SNDS, Système National des Données de Santé

TP53, tumor protein P53

Tx, treatment

Ve/Ven, venetoclax





Saturday 10th December

09:30–11:00, La Nouvelle Orleans Ballroom C

(Ernest N. Morial Convention Center)

Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological I

73

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Ruan et al.

[Abstract](#)

74

Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Phillips et al.

[Abstract](#)

75

Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with *TP53* Mutated and BTKi-Refractory Disease: First Report of the TARMAC Study

Minson et al.

[Abstract](#)

77

Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411

Smith et al.

[Abstract](#)





Saturday 10th December

14:00–15:30, New Orleans Theater C

(Ernest N. Morial Convention Center)

Oral Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological III

232

Phase 1/2 Study of Zilovetamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL)

Lee et al.

[Abstract](#)





Sunday 11th December

14:00–16:00, Hall E (Ernest N. Morial Convention Center)

General Sessions: Plenary Scientific Session

1

Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or as Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized TRIANGLE Trial by the European MCL Network

Dreyling et al.

[Abstract](#)





Monday 12th December

16:30–18:00, La Nouvelle Orleans Ballroom AB

(Ernest N. Morial Convention Center)

Oral Session: 902. Health Services and Quality—Lymphoid Malignancies: Time for Change: Health Care Delivery and Disparities

993

Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma

Bansal et al.

[Abstract](#)





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I

1578

A Phase II Trial of Acalabrutinib in Combination with PI3K δ Inhibitor Umbralisib and the Anti-CD20 Antibody Ublituximab (AU2) in Patients with Previously Untreated Mantle Cell Lymphoma (MCL)

Danilov et al.

[Abstract](#)

1583

Matching-Adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Ibrutinib in Relapsed/Refractory Mantle Cell Lymphoma

Gaitonde et al.

[Abstract](#)

1584

Ibrutinib Plus Bendamustine Plus Rituximab and Rituximab Maintenance (I+BR) Versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone Regimen (R-CHOP) and Rituximab, Cyclophosphamide, Doxorubicin, Bortezomib, Prednisone Regimen (VR-CAP) in First-Line Mantle Cell Lymphoma Patients: An Adjusted Treatment Comparison Using Inverse Probability Weighting

Hernandez-Rivas et al.

[Abstract](#)





Saturday 10th December

17:30–19:30, Hall D (Ernest N. Morial Convention Center)

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster I

1587

Zanubrutinib in Acalabrutinib-Intolerant Patients (Pts) with B-Cell Malignancies

Shadman et al.

[Abstract](#)

1589

Effectiveness and Safety of Ibrutinib in Patients with Mantle Cell Lymphoma (MCL) in Belgian Routine Clinical Practice: 3-Year Follow-up

Vergote et al.

[Abstract](#)

17:30–19:30, Hall D (Ernest N. Morial Convention Center)
Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster I

1797

Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies who were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study

Shah et al.

[Abstract](#)





Sunday 11th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster II

2884

Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Wang et al.

[Abstract](#)

2894

Long-Term Outcomes of Second-Line vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Song et al.

[Abstract](#)

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 705. Cellular Immunotherapies: Late Phase and Commercially Available Therapies: Poster II

3347

Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom

O'Reilly et al.

[Abstract](#)





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 623. Mantle Cell, Follicular, and Other Indolent B Cell Lymphomas: Clinical and Epidemiological: Poster III

4198

Results from a Phase 1/2 Study of Tandem, Bispecific Anti-CD20/Anti-CD19 (LV20.19) CAR T-Cells for Mantle Cell Lymphoma

Shah et al.

[Abstract](#)

4218

Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Wang et al.

[Abstract](#)

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 642. Chronic Lymphocytic Leukemia: Clinical and Epidemiological: Poster III

4437

Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Wang et al.

[Abstract](#)

4443

Use of Ibrutinib in Real Life Settings in France: Results from a Retrospective Observational Study Using the SNDS Database (OSIRIS)

Choquet et al.

[Abstract](#)





Monday 12th December

18:00–20:00, Hall D (Ernest N. Morial Convention Center)

Session: 905. Outcomes Research—Lymphoid

Malignancies: Poster III

4899

Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis

Di et al.

[Abstract](#)





Abbreviations

ALR, acalabrutinib, lenalidomide and rituximab

AU2, acalabrutinib, umbralisib and ublituximab

BR, bendamustine and rituximab

BTK, Bruton tyrosine kinase

BTKi, Bruton tyrosine kinase inhibitor

CAR-T, chimeric antigen receptor T cell

CD, cluster of differentiation

CLL, chronic lymphocytic lymphoma

ECOG, Eastern Cooperative Oncology Group

I+BR, ibrutinib, bendamustine plus rituximab and rituximab maintenance

L, lenalidomide

MCL, mantle cell lymphoma

MRD, minimal residual disease

MZL, marginal zone lymphoma

PI3K δ , phosphatidylinositol 3-kinase delta

Pts, patients

R, rituximab

R-CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone

SNDS, Système National des Données de Santé

TN, treatment-naïve

TP53, tumor protein p53

VR-CAP, rituximab, cyclophosphamide, doxorubicin, bortezomib and prednisone

